C WorldWide Group Holding A S Raises Holdings in Neurocrine Biosciences, Inc. $NBIX

C WorldWide Group Holding A S lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 17.4% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 135,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. C WorldWide Group Holding A S’s holdings in Neurocrine Biosciences were worth $16,968,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Resona Asset Management Co. Ltd. grew its stake in shares of Neurocrine Biosciences by 3.1% during the second quarter. Resona Asset Management Co. Ltd. now owns 52,548 shares of the company’s stock worth $6,604,000 after acquiring an additional 1,581 shares during the last quarter. EFG Asset Management North America Corp. grew its stake in shares of Neurocrine Biosciences by 10.1% during the second quarter. EFG Asset Management North America Corp. now owns 11,175 shares of the company’s stock worth $1,404,000 after acquiring an additional 1,026 shares during the last quarter. Huntington National Bank grew its stake in shares of Neurocrine Biosciences by 26.4% during the second quarter. Huntington National Bank now owns 604 shares of the company’s stock worth $76,000 after acquiring an additional 126 shares during the last quarter. Earned Wealth Advisors LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth about $201,000. Finally, AdvisorShares Investments LLC grew its stake in shares of Neurocrine Biosciences by 2.8% during the second quarter. AdvisorShares Investments LLC now owns 3,666 shares of the company’s stock worth $461,000 after acquiring an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a research note on Monday. The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a research report on Thursday, July 10th. They issued a “buy” rating and a $182.00 target price on the stock. Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, September 22nd. Wall Street Zen upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 2nd. Finally, Canaccord Genuity Group upped their target price on Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $170.26.

Neurocrine Biosciences Trading Up 7.4%

Shares of NASDAQ:NBIX opened at $153.75 on Thursday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $157.67. The company has a market capitalization of $15.33 billion, a PE ratio of 36.78, a PEG ratio of 0.94 and a beta of 0.22. The business has a 50 day moving average of $141.45 and a two-hundred day moving average of $130.70.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.46. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The company had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same period in the previous year, the company posted $1.81 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 27.8% on a year-over-year basis. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.